BRISBANE, Calif., Feb. 1, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that management will host a conference call on February 7th at 12:30 p.m. Eastern Time to discuss interim clinical results from the Phase 1/2 CHAMPIONS and EMPOWERS studies evaluating SB-913 and SB-318 zinc finger nuclease (ZFN) in vivo genome editing product candidates for mucopolysaccharidosis type II (MPS II) and MPS I, respectively. The call will follow presentations earlier that morning at the 2019 WORLDSymposium in Orlando, Florida.
The conference call will be webcast live and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.
The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 4387585. For those unable to listen in at the designated time, a conference call replay will be available for one week following the call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 4387585.
About the WORLDSymposium Presentations
The WORLDSymposium program includes two platform presentations from clinical trials of Sangamo's ZFN in vivo genome editing product candidates, SB-913 (MPS II) and SB-318 (MPS I):
- "CHAMPIONS: A Phase 1/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome)"
Presenter: Joseph Muenzer, MD, PhD, University of North Carolina School of Medicine
February 7th, 2019 at 11:00 a.m. Eastern Time
- "EMPOWERS: A Phase 1/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler Syndrome)"
Presenter: Paul Harmatz, MD, UCSF Benioff Children's Hospital Oakland
February 7th, 2019 at 11:15 a.m. Eastern Time
Also at the WORLDSymposium, Sangamo is scheduled to present a poster and lead a poster discussion regarding updated mouse model data from the ST-920 liver-targeted gene therapy program for Fabry disease:
- "Liver-targeted AAV gene therapy vectors produced by a clinical scale manufacturing process result in high, continuous therapeutic levels of enzyme activity and effective substrate reduction in mouse model of Fabry disease"
Presenter: Marshall Huston, PhD, Sangamo Therapeutics
February 5th, 2019 from 4:30 p.m. – 6:30 p.m. Eastern Time
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-to-host-conference-call-to-review-interim-results-from-phase-12-champions-and-empowers-studies-for-mps-ii-and-mps-i-300788064.html